- cafead   Dec 14, 2023 at 11:02: PM
via A combination of Merck’s blockbuster cancer drug Keytruda and an mRNA vaccine from Moderna has demonstrated positive results at the three-year stage in a Phase IIb study of patients with resected high-risk melanoma following complete resection.
article source
article source